What genetic mutations are commonly found in Lung Cancer

Common Genetic Mutations in Lung Cancer

Genetic mutations are changes in the DNA of cancer cells that can drive tumor growth. Understanding which mutations you or a loved one might have is important because they directly influence treatment options. Let me walk you through the most common ones found in non-small cell lung cancer (NSCLC), which is the most prevalent type.

The Major Driver Mutations

According to the NCCN Guidelines for Non-Small Cell Lung Cancer, doctors typically test for several key mutations because each one responds to specific targeted therapies:

EGFR Mutations (Most Common)

EGFR stands for "epidermal growth factor receptor"—a protein on the surface of lung cells that, when mutated, can fuel cancer growth.

• What they are: The most common EGFR mutations are exon 19 deletions and the L858R point mutation in exon 21
• Who gets them: More common in never-smokers and people of Asian descent
• Why it matters: These mutations typically respond very well to EGFR tyrosine kinase inhibitors (TKIs)—oral medications like osimertinib that specifically target this mutation
• Important note: If EGFR mutations are NOT present, EGFR TKI therapy is not recommended, even in later treatment lines

Less common EGFR variants (about 10% of EGFR-positive cases) include exon 20 insertions and other uncommon mutations. These require specific testing because some respond to certain TKIs while others don't.

KRAS Mutations (Second Most Common)

KRAS is a gene involved in cell growth and survival pathways.

• Prevalence: Found in approximately 25% of lung adenocarcinomas in North American populations—making it the most common mutation overall
• Who gets them: Strongly associated with cigarette smoking history (unlike many other mutations)
• Clinical significance: KRAS mutations are a prognostic biomarker, meaning patients with KRAS mutations tend to have shorter survival than those without them
• Treatment options:
  • For KRAS G12C mutations specifically, FDA-approved targeted drugs like sotorasib and adagrasib are now available
  • For other KRAS mutations, platinum-based chemotherapy (with or without immunotherapy) is typically recommended
  • Single-agent immunotherapy alone has about a 26% response rate in KRAS-mutant metastatic NSCLC

ALK Rearrangements (Gene Fusion)

ALK (anaplastic lymphoma kinase) is a gene that can fuse with other genes, creating an abnormal protein that drives cancer.

• Who gets them: More common in younger patients and never-smokers
• Treatment: ALK rearrangements respond very well to ALK tyrosine kinase inhibitors like crizotinib, alectinib, and brigatinib
• Testing method: Requires specific detection methods; immunohistochemistry or fluorescence in situ hybridization (FISH) are commonly used

ROS1 Rearrangements (Gene Fusion)

Similar to ALK, ROS1 is a gene fusion that creates an abnormal protein.

• Prevalence: Less common than ALK
• Treatment: Responds to ROS1 inhibitors
• Testing: Requires specialized testing to detect the fusion

HER2 (ERBB2) Mutations

HER2 is a growth-promoting protein found on cell surfaces.

• Prevalence: Occurs in approximately 3% of advanced non-squamous NSCLC
• Who gets them: More common in women who have never smoked; these patients have a higher risk of brain metastases
• Treatment: FDA-approved targeted therapy fam-trastuzumab deruxtecan is now available for HER2-mutant lung cancers
• Important: Clinical features like smoking status should NOT be used to decide whether to test—all eligible patients should be tested

MET Alterations

MET is a gene involved in cell growth and survival.

• Types: Include METex14 skipping mutations, MET gene copy number gain, and MET amplification
• Prevalence: METex14 mutations occur in 3-4% of adenocarcinoma NSCLC
• Who gets them: More common in older women who have never smoked
• Testing: Next-generation sequencing (NGS) is the primary detection method, with RNA-based NGS being particularly effective

BRAF Mutations

BRAF is a gene in the MAP/ERK pathway involved in cell growth.

• Prevalence: Less common than EGFR or KRAS
• Treatment: Specific BRAF mutations respond to targeted therapies
• Testing: Requires molecular testing to identify the specific mutation type

How Testing Works

According to NCCN Guidelines, molecular testing for these mutations should be performed using:

• Next-generation sequencing (NGS) — the preferred method because it can detect multiple mutations simultaneously and is particularly good at finding rare variants
• Real-time PCR — commonly used for specific mutations like EGFR
• Tissue or blood samples — both are acceptable; blood-based circulating tumor DNA (ctDNA) testing can be used alongside tissue testing

Important Clinical Principle

A key concept from NCCN Guidelines: these mutations are generally non-overlapping. This means a patient's cancer typically has ONE driver mutation, not multiple ones. However, 1-3% of NSCLC cases may have concurrent alterations, which is why comprehensive testing is important.

Why This Matters for Your Care

Understanding your mutation status is crucial because:

1. It guides treatment selection — targeted therapies work best for specific mutations
2. It predicts response — certain mutations respond better to certain drugs
3. It informs prognosis — some mutations (like KRAS) are associated with different survival outcomes
4. It helps with resistance planning — if you progress on one therapy, knowing your mutation helps doctors select the next treatment

Questions to Ask Your Oncologist

1. What mutations was I tested for, and what were the results?
2. Which mutations, if any, were found in my cancer?
3. What testing method was used, and does it cover all the major driver mutations?
4. If my initial testing didn't find a mutation, should I have broader NGS testing?
5. How do my specific mutations influence my treatment options?
6. If I progress on my current treatment, will you retest to look for resistance mutations?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Sources: NCCN Guidelines for Non-Small Cell Lung Cancer, Version 8.2025; NCCN Guidelines for Patients: Metastatic Non-Small Cell Lung Cancer, 2024